

Pertuzumab plus trastuzumab and chemotherapy for H
gastro-oesophageal junction cancer (JACOB): final analy
placebo-controlled phase 3 study

Lancet Oncology, The
19, 1372-1384

DOI: [10.1016/s1470-2045\(18\)30481-9](https://doi.org/10.1016/s1470-2045(18)30481-9)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Pertuzumab therapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer. <i>Lancet Oncology</i> , The, 2018, 19, 1270-1272.	5.1	8
2	Photothermal and gene therapy combined with immunotherapy to gastric cancer by the gold nanoshell-based system. <i>Journal of Nanobiotechnology</i> , 2019, 17, 80.	4.2	46
3	Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial. <i>Cancer Communications</i> , 2019, 39, 1-10.	3.7	19
4	First-line systemic therapy for advanced gastric cancer: a systematic review and network meta-analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591987772.	1.4	16
5	Targeted and novel therapy in advanced gastric cancer. <i>Experimental Hematology and Oncology</i> , 2019, 8, 25.	2.0	53
6	Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 7098-7112.	3.2	142
7	Clinical and molecular prognostic markers of survival after surgery for gastric cancer: tumor-node-metastasis staging system and beyond. <i>Translational Gastroenterology and Hepatology</i> , 2019, 4, 59-59.	1.5	21
8	Anti-tumor activity of neratinib, a pan-HER inhibitor, in gastric adenocarcinoma cells. <i>European Journal of Pharmacology</i> , 2019, 863, 172705.	1.7	15
9	A Comprehensive PDX Gastric Cancer Collection Captures Cancer Cell-Intrinsic Transcriptional MSI Traits. <i>Cancer Research</i> , 2019, 79, 5884-5896.	0.4	53
10	Targeted neoadjuvant therapy in the HER-2-positive breast cancer patients: a systematic review and meta-analysis. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 379-390.	1.0	5
12	Temporal Modulation of HER2 Membrane Availability Increases Pertuzumab Uptake and Pretargeted Molecular Imaging of Gastric Tumors. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1569-1578.	2.8	27
13	Novel Agents and the Future Perspectives. , 2019, , 367-378.		0
14	EORTC-1203-GITCG - the a€œINNOVATIONa€œ trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group. <i>BMC Cancer</i> , 2019, 19, 494.	1.1	86
15	Pharmacokinetic and exposure-response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 539-550.	1.1	7
16	High prevalence of severe hypovitaminosis D in patients with advanced gastric cancer treated with first-line chemotherapy with or without anti-EGFR-directed monoclonal antibody (EXPAND trial) showing no prognostic impact. <i>European Journal of Cancer</i> , 2019, 116, 107-113.	1.3	2
17	Progress and challenges in HER2-positive gastroesophageal adenocarcinoma. <i>Journal of Hematology and Oncology</i> , 2019, 12, 50.	6.9	44
18	Towards precision oncology for HER2 blockade in gastroesophageal adenocarcinoma. <i>Annals of Oncology</i> , 2019, 30, 1254-1264.	0.6	20
19	Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. <i>Lancet Oncology</i> , The, 2019, 20, 518-530.	5.1	362

#	ARTICLE	IF	CITATIONS
20	Optimal management of gastroesophageal junction cancer. <i>Cancer</i> , 2019, 125, 1990-2001.	2.0	29
21	A phase I/II study of poziotinib combined with paclitaxel and trastuzumab in patients with HER2-positive advanced gastric cancer. <i>Gastric Cancer</i> , 2019, 22, 1206-1214.	2.7	28
22	Genetics of Familial and Sporadic Pancreatic Cancer. <i>Gastroenterology</i> , 2019, 156, 2041-2055.	0.6	52
23	Genomics and Targeted Therapies in Gastroesophageal Adenocarcinoma. <i>Cancer Discovery</i> , 2019, 9, 1656-1672.	7.7	37
24	<p></p>Pertuzumab in the treatment of HER2-positive breast cancer: an evidence-based review of its safety, efficacy, and place in therapy<p></p>. <i>Core Evidence</i> , 2019, Volume 14, 51-70.	4.7	50
25	Human epidermal growth factor receptor 2-positive digestive tumors. <i>Current Opinion in Oncology</i> , 2019, 31, 354-361.	1.1	4
26	Monoclonal Antibodies: Past, Present and Future. <i>Handbook of Experimental Pharmacology</i> , 2019, 260, 81-141.	0.9	41
27	<p></p>Identification of an Activating Mutation in the Extracellular Domain of HER2 Conferring Resistance to Pertuzumab<p></p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 11597-11608.	1.0	12
29	Two steps forward and one step back. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 69-70.	12.5	6
30	<i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i>-Amplified Esophagogastric Cancer. <i>Cancer Discovery</i> , 2019, 9, 199-209.	7.7	115
31	Pharmacotherapy for metastatic esophageal cancer: where do we need to improve?. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 357-366.	0.9	9
32	HER2-targeted therapies â€” a role beyond breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 33-48.	12.5	569
33	Pertuzumab plus trastuzumab and chemotherapy for Japanese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subgroup analysis of the JACOB trial. <i>International Journal of Clinical Oncology</i> , 2020, 25, 301-311.	1.0	8
34	A prospective observational study on the optimal maintenance strategy in HER2-positive advanced gastric cancer treated with trastuzumab-based therapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 287-295.	1.2	12
35	Esophageal carcinoma: Towards targeted therapies. <i>Cellular Oncology (Dordrecht)</i> , 2020, 43, 195-209.	2.1	99
36	Phase II Feasibility and Biomarker Study of Neoadjuvant Trastuzumab and Pertuzumab With Chemoradiotherapy for Resectable Human Epidermal Growth Factor Receptor 2â€™Positive Esophageal Adenocarcinoma: TRAP Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 462-471.	0.8	44
37	Understanding Esophageal Cancer: The Challenges and Opportunities for the Next Decade. <i>Frontiers in Oncology</i> , 2020, 10, 1727.	1.3	97
38	Systemic therapy for advanced gastroesophageal cancers: progress and pitfalls. <i>Translational Gastroenterology and Hepatology</i> , 2020, 5, 53-53.	1.5	6

#	ARTICLE	IF	CITATIONS
39	Precision Medicine to Treat Advanced Gastroesophageal Adenocarcinoma: A Work in Progress. <i>Journal of Clinical Medicine</i> , 2020, 9, 3049.	1.0	12
40	<p>EGLIF-CAR-T Cells Secreting PD-1 Blocking Antibodies Significantly Mediate the Elimination of Gastric Cancer</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 8893-8902.	0.9	25
42	Immune-Directed Molecular Imaging Biomarkers. <i>Seminars in Nuclear Medicine</i> , 2020, 50, 584-603.	2.5	3
43	Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma. <i>The Cochrane Library</i> , 2020, 2020, CD012078.	1.5	12
44	Robotic versus laparoscopic gastrectomy for gastric cancer: a systematic review and meta-analysis. <i>World Journal of Surgical Oncology</i> , 2020, 18, 306.	0.8	31
45	Synthesis and Application of AS1411-Functionalized Gold Nanoparticles for Targeted Therapy of Gastric Cancer. <i>ACS Omega</i> , 2020, 5, 31227-31233.	1.6	20
46	Clinical Implications of Genetic Signatures in Appendiceal Cancer Patients with Incomplete Cytoreduction/HIPEC. <i>Annals of Surgical Oncology</i> , 2020, 27, 5016-5023.	0.7	10
47	Targeted Therapies in Advanced Gastric Cancer. <i>Current Treatment Options in Oncology</i> , 2020, 21, 70.	1.3	133
48	Clinical Impact of Delayed Initiation of Adjuvant Chemotherapy Among Patients With Stage II/III Gastric Cancer: Can We Do Better?. <i>Frontiers in Oncology</i> , 2020, 10, 1149.	1.3	3
49	Antibodyâ€“drug conjugates to treat gastric cancer. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 923-930.	1.4	10
50	Pyrotinib combined with CDK4/6 inhibitor in HER2â€“positive metastatic gastric cancer: A promising strategy from AVATAR mouse to patients. <i>Clinical and Translational Medicine</i> , 2020, 10, e148.	1.7	17
51	Targeted Molecular Therapies in the Treatment of Esophageal Adenocarcinoma, Are We There Yet?. <i>Cancers</i> , 2020, 12, 3077.	1.7	4
52	Gastric cancer. <i>Lancet, The</i> , 2020, 396, 635-648.	6.3	2,084
53	Multimodality Treatment in Metastatic Gastric Cancer: From Past to Next Future. <i>Cancers</i> , 2020, 12, 2598.	1.7	11
54	Censored patients in Kaplanâ€“Meier plots of cancer drugs: An empirical analysis of data sharing. <i>European Journal of Cancer</i> , 2020, 141, 152-161.	1.3	13
55	Does tumor profile in gastric and gastroesophageal (GE) junction cancer justify off-label use of targeted therapy?â€“a narrative review. <i>Annals of Translational Medicine</i> , 2020, 8, 1110-1110.	0.7	3
56	AÂ“case report on the long-term survival of aÂ“patient with HER2-positive metastatic gastric adenocarcinoma and aÂ“short review of the current literature. <i>Memo - Magazine of European Medical Oncology</i> , 2020, 13, 453-458.	0.3	1
57	Targeted therapies for gastroesophageal cancers. <i>Annals of Translational Medicine</i> , 2020, 8, 1104-1104.	0.7	9

#	ARTICLE	IF	CITATIONS
58	Recent Developments of Systemic Chemotherapy for Gastric Cancer. <i>Cancers</i> , 2020, 12, 1100.	1.7	31
59	Diffuse gastric cancer: histologic, molecular, and genetic basis of disease. <i>Translational Gastroenterology and Hepatology</i> , 2020, 5, 52-52.	1.5	20
60	FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers. <i>JAMA Oncology</i> , 2020, 6, 1231.	3.4	12
61	Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 2419-2430.	13.9	681
62	Histology-agnostic drug development “ considering issues beyond the tissue. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 555-568.	12.5	60
63	Strategic design to create HER2-targeting proteins with target-binding peptides immobilized on a fibronectin type III domain scaffold. <i>RSC Advances</i> , 2020, 10, 15154-15162.	1.7	6
64	Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO) Tj ETQq0 0 0.rgBT /Overlock 10 T	0.1	0
65	HER family in cancer progression: From discovery to 2020 and beyond. <i>Advances in Cancer Research</i> , 2020, 147, 109-160.	1.9	27
66	Gastric Cancer: Epidemiology, Risk Factors, Classification, Genomic Characteristics and Treatment Strategies. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4012.	1.8	639
67	Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study. <i>European Journal of Cancer</i> , 2020, 129, 97-106.	1.3	48
68	Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study). <i>Journal of Clinical Oncology</i> , 2020, 38, 1919-1927.	0.8	107
69	Emerging precision therapies for gastric cancer. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020, 5, 299-311.	0.4	1
70	Prognostic and therapeutic molecular markers in the clinical management of esophageal cancer. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 401-411.	1.5	10
71	Human Epidermal Growth Factor Receptor 2 (HER2) in Advanced Gastric Cancer: Current Knowledge and Future Perspectives. <i>Drugs</i> , 2020, 80, 401-415.	4.9	42
72	Utilization and Efficacy of Palliative Chemotherapy for Locally Advanced or Metastatic Gastroesophageal Carcinoma. <i>Anticancer Research</i> , 2020, 40, 965-975.	0.5	12
73	Emerging Targeted Therapies for HER2 Positive Gastric Cancer That Can Overcome Trastuzumab Resistance. <i>Cancers</i> , 2020, 12, 400.	1.7	50
74	New Treatment Options for Advanced Gastroesophageal Tumours: Mature for the Current Practice?. <i>Cancers</i> , 2020, 12, 301.	1.7	7
75	Local and Central Evaluation of HER2 Positivity and Clinical Outcome in Advanced Gastric and Gastroesophageal Cancer“Results from the AGMT GASTRIC-5 Registry. <i>Journal of Clinical Medicine</i> , 2020, 9, 935.	1.0	6

#	ARTICLE	IF	CITATIONS
76	<p>Trastuzumab with FLOT Regimen for the Perioperative Treatment of Resectable HER2 + Advanced Gastric Cancer: A Retrospective Study</p>. Cancer Management and Research, 2020, Volume 12, 2481-2489.	0.9	5
77	Effectiveness of Trastuzumab in Routine Clinical Practice: A Population-based Study of Patients with HER-2-positive Oesophageal, Gastroesophageal and Gastric Cancer. Clinical Oncology, 2021, 33, 202-207.	0.6	4
78	The changing face of gastric cancer: epidemiologic trends and advances in novel therapies. Cancer Gene Therapy, 2021, 28, 390-399.	2.2	23
79	First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811. Future Oncology, 2021, 17, 491-501.	1.1	117
80	Annular atrophic lichen planus induced by anti-HER2 antibodies. Australasian Journal of Dermatology, 2021, 62, 210-212.	0.4	3
81	Potential Molecular Targets in the Setting of Chemoradiation for Esophageal Malignancies. Journal of the National Cancer Institute, 2021, 113, 665-679.	3.0	3
83	Comparison of efficacy outcomes of anticancer drugs between Japanese patients and the overall population. International Journal of Clinical Oncology, 2021, 26, 296-304.	1.0	3
84	Trastuzumab deruxtecan for the treatment of patients with HER2-positive gastric cancer. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592098651.	1.4	16
85	Advanced Gastric Cancer: Current Treatment Landscape and a Future Outlook for Sequential and Personalized Guide: Swiss Expert Statement Article. Oncology Research and Treatment, 2021, 44, 485-494.	0.8	12
86	Importance of Systemic Chemotherapy in Advanced Peritoneal Metastasis. , 2021, , 239-253.		0
87	Optimized EGFR Blockade Strategies in EGFR Addicted Gastroesophageal Adenocarcinomas. Clinical Cancer Research, 2021, 27, 3126-3140.	3.2	11
88	Current treatment and recent progress in gastric cancer. Ca-A Cancer Journal for Clinicians, 2021, 71, 264-279.	157.7	759
89	Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM Registry. Gastric Cancer, 2021, 24, 926-936.	2.7	8
90	Targeted and immunotherapy in the era of personalised gastric cancer treatment. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2021, 50-51, 101738.	1.0	15
91	Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm. Nature Reviews Clinical Oncology, 2021, 18, 473-487.	12.5	139
92	Changes in the therapeutic landscape of oesophago-gastric cancers. Current Opinion in Oncology, 2021, 33, 362-367.	1.1	0
93	Synergistic antitumor effect of the anti-ErbB2 antibodies trastuzumab and H218 on trastuzumab-resistant gastric cancer cells. Oncology Letters, 2021, 21, 400.	0.8	3
94	Personalized therapeutic strategies in HER2-driven gastric cancer. Gastric Cancer, 2021, 24, 897-912.	2.7	6

#	ARTICLE	IF	CITATIONS
95	Trastuzumab deruxtecan for the treatment of HER2-positive advanced gastric cancer: a clinical perspective. <i>Gastric Cancer</i> , 2021, 24, 567-576.	2.7	19
96	Human epidermal growth factor receptor 2 (HER2) in advanced gastric cancer: where do we stand?. <i>Gastric Cancer</i> , 2021, 24, 765-779.	2.7	12
97	Where to Start and What to Do Next: The Sequencing of Treatments in Metastatic Esophagogastric Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, 170-185.	1.8	1
98	Trastuzumab deruxtecan for the treatment of HER2-positive gastric cancer. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 825-830.	1.4	6
99	Novel HER2-Directed Treatments in Advanced Gastric Carcinoma: Another Paradigm Shift?. <i>Cancers</i> , 2021, 13, 1664.	1.7	64
100	Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 811-824.	1.4	16
101	Trends in Chemotherapy Patterns and Survival of Patients with Advanced Gastric Cancer over a 16-Year Period: Impact of Anti-HER2-Targeted Agent in the Real-World Setting. <i>Cancer Research and Treatment</i> , 2021, 53, 436-444.	1.3	4
102	Hopes and failures in front-line advanced HER2-positive gastric cancer therapy. <i>Anti-Cancer Drugs</i> , 2021, Publish Ahead of Print, 675-680.	0.7	2
103	Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 1165-1184.	0.8	54
104	Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4774.	1.8	55
105	Bone Metastases from Gastric Cancer: What We Know and How to Deal with Them. <i>Journal of Clinical Medicine</i> , 2021, 10, 1777.	1.0	8
106	Trastuzumab in combination with 5-Fluorouracil, leucovorin, oxaliplatin and docetaxel as perioperative treatment for patients with human epidermal growth factor receptor 2-positive locally advanced esophagogastric adenocarcinoma: A phase II trial of the Arbeitsgemeinschaft Internistische Onkologie Gastric Cancer Study Group. <i>International Journal of Cancer</i> , 2021, 149, 1322-1331.	2.3	48
107	Roles of Nrf2 in Gastric Cancer: Targeting for Therapeutic Strategies. <i>Molecules</i> , 2021, 26, 3157.	1.7	23
108	Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors. <i>Gastric Cancer</i> , 2021, 24, 913-925.	2.7	61
109	Molecular Determinants of Gastrointestinal Cancers. <i>Advances in Oncology</i> , 2021, 1, 311-325.	0.1	0
110	Evolving treatment paradigms in esophageal cancer. <i>Annals of Translational Medicine</i> , 2021, 9, 903-903.	0.7	9
111	HER2 Expression, Test Deviations, and Their Impact on Survival in Metastatic Gastric Cancer: Results From the Prospective Multicenter VARIANZ Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 1468-1478.	0.8	54
112	A Phase II Study of the Combination of Oxaliplatin, Capecitabine, and Trastuzumab and Chemoradiotherapy in the Adjuvant Setting in Operated Patients With HER2-positive Gastric or Gastroesophageal Junction Cancer (TOXAG Study). <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 301-307.	0.6	8

#	ARTICLE	IF	CITATIONS
113	Neoadjuvant treatment in esophageal cancer—established treatments and new developments reviewed. <i>Annals of Esophagus</i> , 0, 4, 20-20.	0.4	1
114	CDC42EP3 is a key promoter involved in the development and progression of gastric cancer. <i>Carcinogenesis</i> , 2021, 42, 1179-1188.	1.3	4
115	The Right Treatment of the Right Patient: Integrating Genetic Profiling Into Clinical Decision Making in Advanced Gastric Cancer in Asia. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, e166-e173.	1.8	8
116	Mechanisms of Therapeutic Antitumor Monoclonal Antibodies. <i>Cancer Research</i> , 2021, 81, 4641-4651.	0.4	67
117	Targeted therapy in esophageal cancer. <i>Digestive Medicine Research</i> , 0, 4, 29-29.	0.2	4
118	The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021. <i>Cancer Communications</i> , 2021, 41, 747-795.	3.7	323
119	Harnessing biomarkers of response to improve therapy selection in esophago-gastric adenocarcinoma. <i>Pharmacogenomics</i> , 2021, 22, 703-726.	0.6	3
121	Recent Advances in Systemic Treatments for HER-2 Positive Advanced Gastric Cancer. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 4149-4162.	1.0	25
122	Pertuzumab Cardiotoxicity in Patients With HER2-Positive Cancer: A Systematic Review and Meta-analysis. <i>CJC Open</i> , 2021, 3, 1372-1382.	0.7	28
123	HER2-Directed Therapy in Advanced Gastric and Gastroesophageal Adenocarcinoma: Triumphs and Troubles. <i>Current Treatment Options in Oncology</i> , 2021, 22, 88.	1.3	13
124	Development of a Novel Anti-HER2 Monoclonal Antibody H ₂ Mab-181 for Gastric Cancer. <i>Monoclonal Antibodies in Immunodiagnosis and Immunotherapy</i> , 2021, 40, 168-176.	0.8	5
125	Targeted Immunotherapies in Gastrointestinal Cancer: From Molecular Mechanisms to Implications. <i>Frontiers in Immunology</i> , 2021, 12, 705999.	2.2	24
126	Circulating Tumor DNA Analysis Detects <i>FGFR2</i> Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5619-5627.	3.2	27
127	Anti-HER2 monoclonal antibodies intensify the susceptibility of human gastric cancer cells to etoposide by promoting apoptosis, but not autophagy. <i>PLoS ONE</i> , 2021, 16, e0255585.	1.1	4
128	HER2-targeted therapies in gastric cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1876, 188549.	3.3	76
129	Rapidly Evolving Treatment Landscape for Metastatic Esophagogastric Carcinoma: Review of Recent Data. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 4361-4381.	1.0	2
130	Nivolumab as a representative of immune checkpoint inhibitors in late-line treatment for disseminated gastric cancer. <i>Meditinskiy Sovet</i> , 2021, , 96-107.	0.1	0
131	Ovarian cancer with high-level focal ERBB2 amplification responds to trastuzumab and pertuzumab. <i>Gynecologic Oncology Reports</i> , 2021, 37, 100787.	0.3	6

#	ARTICLE	IF	CITATIONS
132	Improving Biologics™ Effectiveness in Clinical Oncology: From the Combination of Two Monoclonal Antibodies to Oligoclonal Antibody Mixtures. <i>Cancers</i> , 2021, 13, 4620.	1.7	9
133	Gastroesophageal adenocarcinoma in older adults: A comprehensive narrative review of management by the young international society of geriatric oncology. <i>Journal of Geriatric Oncology</i> , 2021, , .	0.5	0
134	Cortactin and HER2 as potential markers for dural-targeted therapy in advanced gastric cancer. <i>Clinical and Experimental Medicine</i> , 2022, 22, 403-410.	1.9	2
136	Toward a Treatment Sequencing Strategy: A Systematic Review of Treatment Regimens in Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma. <i>Oncologist</i> , 2021, 26, e1704-e1729.	1.9	14
137	Trastuzumab deruxtecan and other HER2-targeting agents for the treatment of HER2-positive gastric cancer. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1193-1201.	1.1	6
138	A systematic review of HER2 blockade for the curative treatment of gastroesophageal adenocarcinoma: Successes achieved and opportunities ahead. <i>Cancer Treatment Reviews</i> , 2021, 99, 102249.	3.4	6
139	Combined Therapy of Locally Advanced Oesophageal and Gastroesophageal Junction Adenocarcinomas: State of the Art and Aspects of Predictive Factors. <i>Cancers</i> , 2021, 13, 4591.	1.7	0
140	Clinicopathologic features and treatment advances in cancers with HER2 alterations. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1876, 188605.	3.3	11
141	Clinical implications of plasma ctDNA features and dynamics in gastric cancer treated with HER2-targeted therapies. <i>Clinical and Translational Medicine</i> , 2020, 10, e254.	1.7	23
142	Immune checkpoint inhibitor plus anti-HER2 therapy: a new standard for HER2-positive oesophagogastric cancer?. <i>Lancet Oncology</i> , The, 2020, 21, 741-743.	5.1	2
143	Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease. <i>Cancer Discovery</i> , 2021, 11, 308-325.	7.7	49
144	Overcoming Resistance to Targeted Therapies in Gastrointestinal Cancers: Progress to Date and Progress to Come. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 161-173.	1.8	7
145	HER2 heterogeneity is a poor prognosticator for HER2-positive gastric cancer. <i>World Journal of Clinical Cases</i> , 2019, 7, 1964-1977.	0.3	39
146	Immunotherapy and targeted therapy—the new roadmap in cancer treatment. <i>Annals of Translational Medicine</i> , 2019, 7, 595-595.	0.7	25
147	<p>Current Molecular Targeted Agents for Advanced Gastric Cancer</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 4075-4088.	1.0	17
148	Magenkarzinom: Neue molekulare Konzepte. , 0, , .		1
149	Precision medicine in gastric cancer. <i>World Journal of Gastrointestinal Oncology</i> , 2019, 11, 804-829.	0.8	56
150	Recent progress of chemotherapy and biomarkers for gastroesophageal cancer. <i>World Journal of Gastrointestinal Oncology</i> , 2019, 11, 518-526.	0.8	9

#	ARTICLE	IF	CITATIONS
151	Novel Biomarkers for Prediction of Response to Preoperative Systemic Therapies in Gastric Cancer. <i>Journal of Gastric Cancer</i> , 2019, 19, 375.	0.9	11
152	Efficacy, patterns of use and cost of Pertuzumab in the treatment of HER2+ metastatic breast cancer in Singapore: The National Cancer Centre Singapore experience. <i>World Journal of Clinical Oncology</i> , 2020, 11, 143-151.	0.9	3
153	Target Therapy and Immunotherapy in Gastric Cancer. <i>Updates in Surgery Series</i> , 2021, , 225-233.	0.0	0
154	Gastric Cancer: Advanced/Metastatic Disease. <i>UNIPA Springer Series</i> , 2021, , 587-604.	0.1	0
155	Molecular Targets for Gastric Cancer Treatment and Future Perspectives from a Clinical and Translational Point of View. <i>Cancers</i> , 2021, 13, 5216.	1.7	15
156	Green synthesized zinc oxide/neodymium nanocomposites from Avaram Senna flower extract induces apoptosis in gastric cancer AGS cell line through inhibition of the PI3K/AKT/mTOR signaling pathway. <i>Journal of King Saud University - Science</i> , 2021, 33, 101641.	1.6	4
157	Evolving Management Strategies for Metastatic Esophageal and Gastroesophageal Junction Adenocarcinoma. <i>Oncology & Hematology Review</i> , 2018, 14, 82.	0.2	1
159	Results of the use of trastuzumab combined with different chemotherapy regimens in first-line treatment of HER2-positive disseminated gastric cancer. <i>Meditinskiy Sovet</i> , 2019, , 120-127.	0.1	0
160	Development of HER2-targeted Therapies for Gastrointestinal Cancer. <i>European Oncology and Haematology</i> , 2020, 16, 29.	0.0	0
161	Immunotherapy of Gastric and Esophageal Cancers. , 2020, , 213-240.		0
162	Impact of HER2 status in resected gastric or gastroesophageal junction adenocarcinoma in a Western population. <i>Ecancermedalscience</i> , 2020, 14, 1020.	0.6	4
163	Integrating Multiple Omics Data to Search for Driver Genes for Gastric Cancer. <i>Computer Science and Application</i> , 2020, 10, 1820-1833.	0.0	0
164	ISH-based HER2 diagnostics. <i>Der Pathologe</i> , 2021, 42, 62-68.	0.7	3
165	Comparative effectiveness and tolerability of targeted agents combined with chemotherapy in patients with HER2-positive gastroesophageal cancer: A network meta-analysis. <i>Saudi Journal of Gastroenterology</i> , 2021, .	0.5	0
166	Current treatment strategies for patients with only peritoneal cytology positive stage IV gastric cancer. <i>World Journal of Clinical Cases</i> , 2021, 9, 9711-9721.	0.3	1
167	State-of-the-Art of Monoclonal Antibodies for the Treatment of Gastric Cancer. <i>Biologics: Targets and Therapy</i> , 2021, Volume 15, 451-462.	3.0	2
168	microRNA-32-5p targets KLF2 to promote gastric cancer by activating PI3K/AKT signaling pathway. <i>American Journal of Translational Research (discontinued)</i> , 2019, 11, 4895-4908.	0.0	12
169	Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologies. <i>Ca-A Cancer Journal for Clinicians</i> , 2022, 72, 165-182.	157.7	132

#	ARTICLE	IF	CITATIONS
170	Emerging biological drugs for the treatment of gastroesophageal adenocarcinoma. Expert Opinion on Emerging Drugs, 2021, 26, 385-400.	1.0	4
171	Efficacy and safety of targeted drugs in advanced or metastatic gastric and gastroesophageal junction cancer: A network meta-analysis. Journal of Clinical Pharmacy and Therapeutics, 2021, , .	0.7	1
172	Novel Biomarkers of Gastric Adenocarcinoma: Current Research and Future Perspectives. Cancers, 2021, 13, 5660.	1.7	16
173	HER2 in gastric adenocarcinoma: where do we stand today?. Personalized Medicine, 2022, 19, 67-78.	0.8	1
174	Case series of docetaxel, trastuzumab, and pertuzumab (DTP) as first line anti-HER2 therapy and ado-trastuzumab emtansine (T-DM1) as second line for recurrent or metastatic HER2-positive salivary duct carcinoma. Oral Oncology, 2022, 125, 105703.	0.8	15
175	Safety and efficacy of HER2 blockade by trastuzumab-based chemotherapy-containing combination strategies in HER2+ gastroesophageal adenocarcinoma. ESMO Open, 2022, 7, 100360.	2.0	5
177	Stomach: The Standard of Care ± HER2. , 2021, , 75-88.		0
178	Emerging HER2-directed therapeutic agents for gastric cancer in early phase clinical trials. Expert Opinion on Investigational Drugs, 2022, 31, 59-78.	1.9	8
179	Current status and future perspectives in HER2 positive advanced gastric cancer. Clinical and Translational Oncology, 2022, 24, 981-996.	1.2	15
180	Pharmaceutical advances in the treatment of gastric adenocarcinoma. Expert Opinion on Pharmacotherapy, 2022, , 1-11.	0.9	0
181	Personalized Treatment of Advanced Gastric Cancer Guided by the MiniPDX Model. Journal of Oncology, 2022, 2022, 1-11.	0.6	3
182	Editorial: Molecular Biomarkers for Gastric Cancer. Frontiers in Oncology, 2022, 12, 850373.	1.3	1
183	Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial. Lancet Oncology, The, 2022, 23, 259-269.	5.1	58
184	Esophageal cancer: emerging therapeutics. Expert Opinion on Therapeutic Targets, 2022, 26, 107-117.	1.5	51
185	Dramatic Response to Trastuzumab Deruxtecan Rechallenge in a Patient with HER2-Positive Gastric Cancer: A Case Report. American Journal of Case Reports, 2022, 23, e935600.	0.3	1
186	Schisandrin B suppresses gastric cancer cell growth and enhances the efficacy of chemotherapy drug 5-FU in vitro and in vivo. European Journal of Pharmacology, 2022, 920, 174823.	1.7	15
187	The dawn of precision medicine in diffuse-type gastric cancer. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592210830.	1.4	19
188	Top advances in esophageal/gastroesophageal junction cancers in 2021. Cancer, 2022, 128, 1894-1899.	2.0	1

#	ARTICLE	IF	CITATIONS
190	Retrospective Study on the Efficacy and Safety of Pyrotinib-Based Therapy for HER2-Positive Nonbreast Advanced Solid Tumors. <i>Journal of Oncology</i> , 2022, 2022, 1-8.	0.6	0
191	Chemorefractory Gastric Cancer: The Evolving Terrain of Third-Line Therapy and Beyond. <i>Cancers</i> , 2022, 14, 1408.	1.7	2
192	Trastuzumab/pertuzumab combination therapy stimulates antitumor responses through complement-dependent cytotoxicity and phagocytosis. <i>JCI Insight</i> , 2022, 7, .	2.3	14
193	Systemic therapy for gastric cancer: Perioperative strategies and beyond. <i>Journal of Surgical Oncology</i> , 2022, 125, 1151-1160.	0.8	10
195	Interest of the Addition of Taxanes to Standard Treatment in First-Line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective Patients. <i>Frontiers in Oncology</i> , 2022, 12, 763926.	1.3	0
197	Translational Strategies to Target Metastatic Bone Disease. <i>Cells</i> , 2022, 11, 1309.	1.8	4
198	Therapeutic Advances and Challenges in the Management of HER2-Positive Gastroesophageal Cancers. <i>Diseases (Basel, Switzerland)</i> , 2022, 10, 23.	1.0	1
199	Tucatinib has Selective Activity in HER2-Positive Cancers and Significant Combined Activity with Approved and Novel Breast Cancerâ€œTargeted Therapies. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 751-761.	1.9	10
200	Analysis of a Real-World Progression Variable and Related Endpoints for Patients with Five Different Cancer Types. <i>Advances in Therapy</i> , 2022, 39, 2831-2849.	1.3	5
201	An overview of the preclinical discovery and development of trastuzumab deruxtecan: a novel gastric cancer therapeutic. <i>Expert Opinion on Drug Discovery</i> , 2022, 17, 427-436.	2.5	2
204	Validity of the Cancer and Aging Research Group Predictive Tool in Older Japanese Patients. <i>Cancers</i> , 2022, 14, 2075.	1.7	10
205	Caveolin-1 temporal modulation enhances antibody drug efficacy in heterogeneous gastric cancer. <i>Nature Communications</i> , 2022, 13, 2526.	5.8	10
206	Putative Clinical Potential of ERBB2 Amplification Assessment by ddPCR in FFPE-DNA and cfDNA of Gastroesophageal Adenocarcinoma Patients. <i>Cancers</i> , 2022, 14, 2180.	1.7	6
207	Evolution of predictive and prognostic biomarkers in the treatment of advanced gastric cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, , .	1.2	4
208	Approach to Resectable Gastric Cancer: Evolving Paradigm of Neoadjuvant and Adjuvant Treatment. <i>Current Treatment Options in Oncology</i> , 2022, 23, 1044-1058.	1.3	4
209	Molecular pathogenesis and emerging targets of gastric adenocarcinoma. <i>Journal of Surgical Oncology</i> , 2022, 125, 1079-1095.	0.8	6
211	An Immune-Related Prognostic Signature Predicts Overall Survival in Stomach Adenocarcinomas. <i>Frontiers in Genetics</i> , 2022, 13, .	1.1	2
212	The HIF-1 α as a Potent Inducer of the Hallmarks in Gastric Cancer. <i>Cancers</i> , 2022, 14, 2711.	1.7	9

#	ARTICLE	IF	CITATIONS
213	Resistance mechanisms to HER2-targeted therapy in gastroesophageal adenocarcinoma: A systematic review. <i>Cancer Treatment Reviews</i> , 2022, 108, 102418.	3.4	14
214	Stem Cell Biomarkers and Tumorigenesis in Gastric Cancer. <i>Journal of Personalized Medicine</i> , 2022, 12, 929.	1.1	2
215	FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2-Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group. <i>Journal of Clinical Oncology</i> , 2022, 40, 3750-3761.	0.8	28
216	Efficacy of Ipilimumab vs FOLFOX in Combination With Nivolumab and Trastuzumab in Patients With Previously Untreated ERBB2-Positive Esophagogastric Adenocarcinoma. <i>JAMA Oncology</i> , 0, .	3.4	17
217	N6-Methyladenosine Modification Patterns and Tumor Microenvironment Immune Characteristics Associated With Clinical Prognosis Analysis in Stomach Adenocarcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	7
218	A Case Report of Immunotherapy-Resistant MSI-H Gastric Cancer with Significant Intrapatient Tumoral Heterogeneity Characterized by Histologic Dedifferentiation. <i>Journal of Clinical Medicine</i> , 2022, 11, 3413.	1.0	1
219	Current State of Targeted Therapy and Immunotherapy in Advanced Gastric and Gastro-oesophageal Cancers. <i>Touch Reviews in Oncology & Haematology</i> , 2022, 18, 16.	0.1	0
220	Targeting MET amplification in Gastro-oesophageal (GO) malignancies and overcoming MET inhibitor resistance: challenges and opportunities. <i>Expert Review of Gastroenterology and Hepatology</i> , 2022, 16, 601-624.	1.4	0
221	From Anti-HER-2 to Anti-HER-2-CAR-T Cells: An Evolutionary Immunotherapy Approach for Gastric Cancer. <i>Journal of Inflammation Research</i> , 0, Volume 15, 4061-4085.	1.6	1
222	The effectivity of targeted therapy and immunotherapy in patients with advanced metastatic and non-metastatic cancer of the esophagus and esophago-gastric junction. <i>Updates in Surgery</i> , 2023, 75, 313-323.	0.9	8
223	PLOD3 contributes to HER-2 therapy resistance in gastric cancer through FoxO3/Survivin pathway. <i>Cell Death Discovery</i> , 2022, 8, .	2.0	5
224	Histology-agnostic approvals for antibody-drug conjugates in solid tumours: is the time ripe?. <i>European Journal of Cancer</i> , 2022, 171, 25-42.	1.3	9
225	Neoadjuvant treatment in gastric cancer. <i>Memo - Magazine of European Medical Oncology</i> , 0, .	0.3	1
226	HER2 Inhibition in Gastric Cancer—Novel Therapeutic Approaches for an Established Target. <i>Cancers</i> , 2022, 14, 3824.	1.7	8
227	Targeting the complexity of ERBB2 biology in gastroesophageal carcinoma. <i>Annals of Oncology</i> , 2022, 33, 1134-1148.	0.6	6
228	HER2 status is positively associated with vessel invasion of colorectal cancer: a retrospective large cohort study. <i>International Journal of Colorectal Disease</i> , 2022, 37, 2061-2067.	1.0	3
229	HERIZON-GEA-01: Zanidatamab + chemo± tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma. <i>Future Oncology</i> , 2022, 18, 3255-3266.	1.1	13
230	Postoperative outcomes in robotic gastric resection compared with laparoscopic gastric resection in gastric cancer: A meta-analysis and systemic review. <i>Health Science Reports</i> , 2022, 5, .	0.6	1

#	ARTICLE	IF	CITATIONS
231	Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A. <i>ESMO Open</i> , 2022, 7, 100563.	2.0	15
232	European-Australasian consensus on the management of advanced gastric and gastro-oesophageal junction cancer: current practice and new directions. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211188.	1.4	1
233	Deviating HER2 test results in gastric cancer: analysis from the prospective multicenter VARIANZ study. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	0
234	Population pharmacokinetics of zanidatamab, an anti-HER2 bipolar antibody, in patients with advanced or metastatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 90, 399-408.	1.1	4
235	Ki-67 Index Provides Long-Term Survival Information for Early-Stage HER2-Low-Positive Breast Cancer: A Single-Institute Retrospective Analysis. <i>Journal of Oncology</i> , 2022, 2022, 1-9.	0.6	1
236	HER2-targeted advanced metastatic gastric/gastroesophageal junction adenocarcinoma: treatment landscape and future perspectives. <i>Biomarker Research</i> , 2022, 10, .	2.8	7
237	Pertuzumab, trastuzumab, and chemotherapy in HER2-positive gastric/gastroesophageal junction cancer: end-of-study analysis of the JACOB phase III randomized clinical trial. <i>Gastric Cancer</i> , 2023, 26, 123-131.	2.7	13
238	Molecular Pathology of Gastric Cancer. <i>Journal of Gastric Cancer</i> , 2022, 22, 264.	0.9	6
239	Targeting HER2 in metastatic gastroesophageal adenocarcinomas: What is new?. <i>Bulletin Du Cancer</i> , 2022, , .	0.6	1
240	Tumor Microenvironment, Clinical Features, and Advances in Therapy for Bone Metastasis in Gastric Cancer. <i>Cancers</i> , 2022, 14, 4888.	1.7	7
242	KN026 (anti-HER2 bispecific antibody) in patients with previously treated, advanced HER2-expressing gastric or gastroesophageal junction cancer. <i>European Journal of Cancer</i> , 2023, 178, 1-12.	1.3	9
243	Recent Trends and Advancements in the Diagnosis and Management of Gastric Cancer. <i>Cancers</i> , 2022, 14, 5615.	1.7	8
244	Prognostic and clinical significance of HER-2 low expression in early-stage gastric cancer. <i>BMC Cancer</i> , 2022, 22, .	1.1	10
245	Current developments in gastric cancer: from molecular profiling to treatment strategy. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2023, 20, 155-170.	8.2	61
246	HER2 Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB Trial. <i>Clinical Cancer Research</i> , 2023, 29, 571-580.	3.2	5
247	HER2-Positive Gastroesophageal Cancers Are Associated with a Higher Risk of Brain Metastasis. <i>Cancers</i> , 2022, 14, 5754.	1.7	3
248	Comparative efficacy and tolerability of targeted and immunotherapy combined with chemotherapy as first-line treatment for advanced gastric cancer: a Bayesian network meta-analysis. <i>Scientific Reports</i> , 2022, 12, .	1.6	4
249	Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2023, 41, 1470-1491.	0.8	46

#	ARTICLE	IF	CITATIONS
250	Pharmacokinetics of biologics in gastric cancer. <i>Clinical and Translational Science</i> , 2023, 16, 564-574.	1.5	2
251	Molecular Pathways and Mechanisms of HER2 in Cancer Therapy. <i>Clinical Cancer Research</i> , 2023, 29, 2351-2361.	3.2	2
252	Next-generation sequencing and molecular therapy. <i>Clinical Medicine</i> , 2023, 23, 65-69.	0.8	2
253	Korean Practice Guidelines for Gastric Cancer 2022: An Evidence-based, Multidisciplinary Approach. <i>Journal of Gastric Cancer</i> , 2023, 23, 3.	0.9	66
254	Challenges and future of HER2-positive gastric cancer therapy. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	3
255	Current progress and challenges of immunotherapy in gastric cancer: A focus on CAR-T cells therapeutic approach. <i>Life Sciences</i> , 2023, 318, 121459.	2.0	6
256	Breakthroughs in the Systemic Treatment of HER2-Positive Advanced/Metastatic Gastric Cancer: From Singlet Chemotherapy to Triple Combination. <i>Journal of Gastric Cancer</i> , 0, 23, .	0.9	3
257	Definition, diagnosis and treatment of oligometastatic oesophagogastric cancer: A Delphi consensus study in Europe. <i>European Journal of Cancer</i> , 2023, 185, 28-39.	1.3	11
258	Overview of Chemotherapy for Gastric Cancer. <i>Journal of Clinical Medicine</i> , 2023, 12, 1336.	1.0	10
259	Identification and characterization of a novel molecular classification incorporating oxidative stress and metabolism-related genes for stomach adenocarcinoma in the framework of predictive, preventive, and personalized medicine. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	8
260	Recent advances in the management of gastric adenocarcinoma patients. <i>Faculty Reviews</i> , 0, 12, .	1.7	1
261	Perioperative Tailored Treatments for Gastric Cancer: Times Are Changing. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4877.	1.8	5
262	Optimal treatment strategy after first-line induction therapy in advanced HER2-positive oeso-gastric adenocarcinoma—a retrospective, international, multicentric AGEO study. <i>Gastric Cancer</i> , 2023, 26, 425-437.	2.7	0
263	An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity. <i>Nature Communications</i> , 2023, 14, .	5.8	23
264	Recent Advances in the Systemic Treatment of Localized Gastroesophageal Cancer. <i>Cancers</i> , 2023, 15, 1900.	1.7	2
266	Multi-Targeting Anticancer Activity of a New 4-Thiazolidinone Derivative with Anti-HER2 Antibodies in Human AGS Gastric Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6791.	1.8	2
268	Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics. <i>Pharmaceuticals</i> , 2023, 16, 614.	1.7	18
282	Palliative Chemotherapy: CTx Regimen (First-Line, Second-Line, Targeted Therapies, and Immunotherapy). , 2023, , 129-138.		0

#	ARTICLE	IF	CITATIONS
283	Case Report: A rare synchronous multiple gastric carcinoma achieved progression-free disease through NGS-guided serial treatment. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
288	Targeted therapy and drug resistance in gastric and pancreatic cancer. , 2023, , 183-206.		0
312	Current and Future Biomarkers in Esophagogastric Adenocarcinoma. <i>Journal of Gastrointestinal Cancer</i> , 0, , .	0.6	0